Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107912 · ClinicalTrials.gov registry record · Phase 1
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
NCT01107912: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT01107912 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 155 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (158% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01107912, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
Study Summary
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
Primary Outcome
Maximum Platelet Aggregation (MPA) to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). Lower MPA values reflect stronger platelet inhibition, whereas higher MPA values reflect weaker inhibition.
Interventions
- DRUG clopidogrel
- DRUG prasugrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
What the finished NCT01107912 record still lists
NCT01107912 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (158% higher).
The record links to 0 conditions, and to 2 interventions - of which clopidogrel is the first listed.
NCT01107912 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01107912 about?
NCT01107912 is a clinical study titled "Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease". The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
What is the current status of trial NCT01107912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2010-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01107912?
The interventions under investigation include: clopidogrel (DRUG), prasugrel (DRUG).
Who is sponsoring clinical trial NCT01107912?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01107912's enrollment target sits among peer trials
155 352nd of 2000 higher than 1,645 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia